Research programme: amyotrophic lateral sclerosis therapy - ALS Therapy Development Institute

Drug Profile

Research programme: amyotrophic lateral sclerosis therapy - ALS Therapy Development Institute

Alternative Names: ALS TDI 00846; TDI 104; TDI 142; TDI 158; TDI 163; TDI 168; TDI 186; TDI 197; TDI 201; TDI 202; TDI 206; TDI 207; TDI 208; TDI 209; TDI 210; TDI 211; TDI 28; TDI 53

Latest Information Update: 22 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALS Therapy Development Institute
  • Class Gene therapies; Small molecules
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 30 Mar 2010 ALS TDI 00846 is available for partnering for clinical development (http://www.als.net)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top